Tullis Health Investors Welcomes Bob Crutchfield to Its Team
Tullis Health Investors is pleased to announce the addition of Robert L. Crutchfield as an operating partner. Utilizing his extensive experience in healthcare operations and healthcare venture capital investing, Bob will support Tullis funds with deal sourcing, deal review, due diligence, portfolio company support, and fundraising.
Bob began his healthcare career as an operator at Surgical Laser Technologies, then moved on to Cardinal Health as general manager of Snowden Pencer and vice president of new ventures. Bob subsequently led pharmaceutical sales at US Oncology, where he oversaw six operating businesses representing $2.5 billion in annual revenues.
Following his successful operating career, Bob joined Harbert Management Corporation as a senior partner and led their healthcare practice. There he held positions on twelve portfolio company boards, including Shipt – acquired by Target in 2017, Wellcentive – acquired by Royal Philips in 2016, nContact – acquired by Atricure in 2014, Novamin – acquired by GSK in 2009, and IngagePatient Inc., where he was executive chairman.
Most recently, Bob launched and led the American Cancer Society’s BrightEdge Philanthropic Venture Fund, targeting investments in advanced therapies to treat, detect, and prevent all types of cancer. During his tenure, he led four investments, one of which completed a successful initial public offering in less than a year, and created a prestigious advisory board comprised of some of the leading scientists, physicians, and innovators in oncology.
Bob serves on the Board of Trustees of the Georgia Research Alliance, as well as the boards of the Southeast Life Sciences Association, the Southern Capital Forum, the Global Center for Medical Innovation, and Health Connect South.
Bob is a graduate of the University of Georgia and holds Bachelor of Science degrees in Political Science and Chemistry.